|[April 24, 2012]
Dr. Reddy's Announces the Launch of Olanzapine Tablets
HYDERABAD, India --(Business Wire)--
Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has
launched Olanzapine Tablets (2.5 mg, 5 mg, 7.5 mg, 10mg, 15 mg),
a bioequivalent generic version of ZYPREXA® Tablets in the US market on
April 23, 2012 following the approval by the United States Food & Drug
Administration (USFDA) of Dr. Reddy's ANDA for Olanzapine Tablets. Dr.
Reddy's Olanzapine Tablets in 20 mg had been awarded a 180-day period of
marketing exclusivity in the U.S. on October 26, 2011 which was
commercialized through a commercial, manufacture and supply agreement
with Teva Pharmaceutical Industries Ltd.
The ZYPREXA® Tablets brand and generic had combined U.S. sales of
approximately $3.28 billion for the most recent twelve months ending
January 2012 according to IMS Health.
Dr. Reddy's Olanzapine Tablets in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and
20 mg strengths are available in 30 and 500 count bottles.
This press release inludes forward-looking statements, as defined in
the U.S. Private Securities Litigation Reform Act of 1995. We have based
these forward-looking statements on our current expectations and
projections about future events. Such statements involve known and
unknown risks, uncertainties and other factors that may cause actual
results to differ materially. Such factors include, but are not limited
to, changes in local and global economic conditions, our ability to
successfully implement our strategy, the market acceptance of and demand
for our products, our growth and expansion, technological change and our
exposure to market risks. By their nature, these expectations and
projections are only estimates and could be materially different from
actual results in the future.
About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is an integrated global
pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses -
Pharmaceutical Services and Active Ingredients, Global Generics and
Proprietary Products - Dr. Reddy's offers a portfolio of products and
services including APIs, custom pharmaceutical services, generics,
biosimilars, differentiated formulations and NCEs. Therapeutic focus is
on gastro-intestinal, cardiovascular, diabetology, oncology, pain
management, anti-infective and pediatrics. Major markets include India,
USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New
Zealand. For more information, log on to: www.drreddys.com
ZYPREXA® is a trademark of Eli Lilly and Company.
IMS National Sales Perspectives: Retail and Non-Retail MAT April 2012
[ Back To TMCnet.com's Homepage ]